Human physiologically based pharmacokinetic model for ACE inhibitors: Ramipril and ramiprilat

Pharmacology, Toxicology and Pharmaceutical Science

• Dipeptidyl Carboxypeptidase Inhibitor 100%
• Ramipril 100%
• Ramiprilat 100%
• Pharmacokinetics 100%
• Dipeptidyl Carboxypeptidase 66%
• Binding Site 33%
• Prodrug 22%
• Enzyme Inhibition 11%
• Dilution Assay 11%

Keyphrases

• Physiologically-based Pharmacokinetic Model 100%
• Ramipril 100%
• Angiotensin-converting Enzyme Inhibitor (ACEi) 100%
• Angiotensin-converting Enzyme 27%
• Binding Site 16%
• Pharmacokinetics 11%
• Metabolism 11%
• Prodrug 11%
• Binding Kinetics 11%
• Enzyme Binding 11%
• Human Pharmacokinetics 11%
• Liver 5%
• Kidney 5%
• High Affinity 5%
• Oral Dose 5%
• Non-equilibrium 5%
• Drug Class 5%
• Extrusion 5%
• Low Affinity 5%
• Sodium Chloride 5%
• Dissociation Rate 5%
• Active Form 5%
• Subnanomolar 5%
• Intracellular Uptake 5%
• Model Features 5%
• Angiotensin-converting Enzyme Inhibition 5%
• Plasma Protein Binding 5%
• In Vitro Inhibition 5%
• Model Specification 5%
• Renal Clearance 5%
• Equilibrium Time 5%
• Total-body 5%